Forma Therapeutics. (3/13/17). "Press Release: Forma Therapeutics Announces Achievement of First Clinical Development Milestone in Partnership with Boehringer Ingelheim". Watertown, MA.

	Organisation	Forma Therapeutics Inc.
	Group	Forma Therapeutics (Group)
	Organisation 2	Boehringer Ingelheim (Group)
	Product	cancer drug
	Product 2	drug development
	Person	Watson, Kari (MacDougall Biomedical Communications 201601)

FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, today announced the achievement of a clinical development milestone in their alliance with Boehringer Ingelheim (BI). The partnership focuses on the discovery and development of novel drug candidates against protein-protein interactions for the treatment of cancer. Financial milestones payable to FORMA for this achievement have not been disclosed.

“FORMA’s discovery and early clinical development successes, across our wholly-owned pipeline as well as programs in collaboration with pharmaceutical partners, accentuates the value of a unique compound collection and productivity of talented teams across collaborative networks” said John Hohneker, M.D., EVP and Head of Research and Development at FORMA. “We are pleased to see tractable progress of protein-protein modulators and to have contributed to BI’s clinical candidate pipeline, enabled by the collective grit of R&D teams, boldly and courageously taking on such challenging programs.”

“We are pleased to see tractable progress of protein-protein modulators and to have contributed to BI’s clinical candidate pipeline, enabled by the collective grit of R&D teams, boldly and courageously taking on such challenging programs.”

About FORMA

FORMA Therapeutics' scientists are passionate about discovering and developing medicines that will make a difference in oncology, inflammation & immunity, and other serious diseases. The Company’s fully integrated R&D team drives discovery and early clinical development of therapeutics for qualified targets in the areas of epigenetics, protein homeostasis and metabolism. Leveraging a world class network of academic investigators, clinical experts and partners, FORMA combines deep biology insight, chemistry expertise and early clinical development capabilities, to create drug candidates that will ultimately provide profound patient benefit.

FORMA is headquartered in Watertown, MA near the epicenter of the Cambridge Life Sciences cluster, with additional chemistry operations in Branford, CT. www.formatherapeutics.com

Join our conversation on Twitter @FORMAInc.

Media Contact

For FORMA Therapeutics
Kari Watson +1 781-235-3060
kwatson@macbiocom.com
MacDougall Biomedical Communications

Record changed: 2023-06-05